drugset / Trial / NCT00642538
A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus
RandomizedCrossoverDouble-blindTreatment
Summary
20 eligible subjects will be enrolled into the treatment phase of the trial.
Timeline
- Start
- 2008-02
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Exenatide | Peptide | 10 ug | Subcutaneous |
| Subject | GLP-1 (7-36) amide | Unknown | 1.5 mg | Inhaled |